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Summary
The high rate of persistent hyperglycemia, termed primary nonfunction, afterislet allotransplantation
in C57BL/6 mice recipients of B10.BR strain islets, as compared with B10.BR recipients of
C57BL/6 islets, led to a series of experiments to determine whether islet allograft primary
nonfunction was attributable to technical aspects of the transplant procedure or whether it was
a consequence of alloimmunity. Primary nonfunction was prevented by systemic pharmacologic
immunosuppression of the host with cyclosporine. Selective immunodepletion of host CD4+
and CD8+ T lymphocytes significantly extended the time of classic rejection but did not sig-
nificantly affect the rate of primary nonfunction. However, modulation of macrophages by
administration to the host of silica completely abolished primary nonfunction. These observations,
in conjunction with the immunnhistological findings of intense macrophage infiltration in islet
allografts from recipients exhibiting persistent post-transplant hyperglycemia, support the hypothesis
that primary nonfunction results from a cell-mediated host-immune response of rapid onset that
is dependent on macrophages or macrophage byproducts as the main effectors.
I
mmediate and permanent failure of an organ or tissue allo-
graftin which there is never any discernible function (termed
primary nonfunction) is usually ascribed to nonimmunologic
events. Vascularized organ grafts may fail to function because
of technical factors such as prolonged preservation (1) or ar-
terial or venous thrombosis (2, 3). In free grafts of cells or
tissues, such as adult islets ofLangerhans, primary nonfunc-
tion has been thought to reflect tissue injury during procure-
ment (4) or implantation of an inadequate functional mass
of tissue (5, 6).
Allograft primary nonfunction may also be caused by im-
munologic phenomena. In immediately vascularized solid
organs such as kidneys, the predominant immunologically
defined cause of primary nonfunction is hyperacute rejection.
This phenomenon occurs in recipients with preformed an-
tidonor antibodies directed against MHC or blood group an-
tigens (7, 8). In free tissue grafts requiring neovasculariza-
tion, such as bone marrow, failure of engraftment (termed
allogeneic resistance) appears to be mediated, at leastin part,
by NK cells (9-12) . Except for bone marrow, nonhumoral,
cell-mediated immediate destruction or inhibition ofprimary
graft function has not been described.
In clinical and experimental studies ofpancreatic islet trans-
plantation, the distinction between immunologic and nonim-
munologic causes of allograft primary nonfunction has not
been made. In the few clinical trials of adult human islet al-
lotransplantation (13-17), graft function, demonstrated by
at least transient achievement of a euglycemic, insulin-inde-
pendent state, has occurred only rarely, and the cause of islet
allograft failure has not been elucidated. Although islet al-
lograft primary nonfunction may be the consequence oftech-
nicalproblems ofthe transplant procedure itself, such as having
an inadequate mass of functional islets, the yields reported
from humanpancreas islet isolations are theoretically sufficient,
and islet autografts after total pancreatectomy for treatment
of benign disease have prevented the occurrence of diabetes
(18) . This observation, based upon a limited number ofcases,
suggests that an immune mechanism that affects /3 cells might
be responsible for the immediate failure of human islet al-
lografts.
Primary nonfunction also occurs in rodent models of islet
allotransplantation. In previous publications, we and others
have considered such an outcome to be due to technical factors
(19-21), and have excluded recipientsthat never exhibited graft
function from data analysis. A review ofour experience with
adult islet transplantation in inbred mice, however, showed
that primary nonfunction was confined to allograft recipients,
and was dependent on the donor-recipient combination used,
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observations, we sought to determinewhether islet allograft
primarynonfunctionwas a consequence ofearlyalloimmune
events, and to determine the roles of Mac-1+ cells and CD4+
and CD8+ T lymphocytes in these events, as well as their
role in the ultimate destruction of allogeneic islets.
Materials and Methods
Mice and Induction ofDiabetes.
￿
Adult male C57BL/6J (H-26)
andB10.BRSg/SnJ (H-21) mice were obtained from TheJackson
Laboratory (Bar Harbor, ME), and were used as both donors and
recipients. The strains ofmice were genetically disparate over the
H-2, Qa, andTla regions, butotherwisehad similargenetic back-
grounds. Therewere no significant differences between theB10.BR
andC57BL/6strainsin thenormal nonfastingbloodglucose values
(overall mean value 143 ± 5.2 mg/dl, 16 determinants). Recipient
mice were made diabetic by a single intraperitoneal injection of
streptozotocin, 220 mg/kg body weight (a gift from Upjohn
Laboratories, Kalamazoo, MI). All recipient mice were hyper-
glycemic for at least 1 wk before islet transplantation, and only
those with nonfasting bloodglucose levels >350 mg/dl were used.
There were no strain differences in the degree of hyperglycemia
attained by intraperitoneal streptozotocin.
Islet Isolation and Transplantation.
￿
Donormice were fasted over-
nightpreceding islet isolation. For each transplant, islets were iso-
latedfrom 8-12 donorpancreases by thesequential collagenase (Type
I; Sigma Chemical Co., St. Louis, MO) digestion technique, and
were hand picked free ofcontaminating lymphoid andacinar tissue
as previously described (19, 21). This method yielded a range of
75-100 islets per donor pancreas. During ether-inducedanesthesia
ofthe diabetic recipient mouse, thekidney was exposed via a sub-
costal incision, anddonor islets were transplantedbeneath thekidney
capsule using a 23-gauge butterfly needle.
Cyclosporine.
￿
Some islet allograft recipients were administered
cyclosporine (20 mg/ml dissolved in olive oil) subcutaneously be-
ginning at the time of transplant and daily thereafter for 100 d.
Control groups of nontransplanted diabetic mice (n = 5) and
recipients of isogeneicislets (n = 5) were given 20 mg/kg of cy-
closporine daily for >100 d. Nonfasting blood glucose levels were
determined in experimental andcontrol animals daily for the first
30 d post-transplant and then three times per week.
Immunodepletion of T Cell Subsets.
￿
Hybridomas secreting anti-
CD4 mAb (22) (GK 1.5, rat anti-mouse IgG2b), and anti-CD8
mAb (23) (2.43; rat anti-mouse IgG2b) were obtained from the
American Type CultureCollection (Rockville, MD). Theexpanded
hybridomas were implantedin outbreed nu/nu C57BL/6 strain mice.
The antibodies were precipitated from ascites fluid with 50% am-
monium sulfateand dialyzed against PBS. Some diabetic C57BL/6
mice received 750 wg of anti-CD4 or anti-CD8 mAb intraperi-
toneally (N30 al) on days -1, 0, 1, 3, and 5, relative to the time
of islet transplantation.
In vivo efficacy of the mAbs to specifically immunodeplete the
Tlymphocyte cell subset ofinterest wasassessed in nontransplanted
control mice by FACS (FACSIV; Becton Dickinson &Co., Moun-
tain View, CA) analysis ofperitoneal andspleniclymphocytes.After
administration ofantibody in nontransplantedcontrol animals, the
CD4+ or CD8+ T cell subsets in the splenic and intraperitoneal
compartments were decreased to 15-20% of the normal mean
proportions, and remained decreased over a 28-d time course.
Depletion ofMacrophages.
￿
Silica administered intraperitoneally
(1 mg/d for five consecutive days) in a series of control C57BL/6
292 Islet Allograft Primary Nonfunction
mice resulted in progressive diminution in the number of Mac-1',
granular, large-cell peritoneal macrophages (as determined by FRCS
analysis), over thecourse o£3-4wk, results consistent with previous
reports (24). Forsubsequent C57BL/6recipients ofB10.BR islets,
diabetes wasinduced3wk aftersilica administration, andislet trans-
plantation was performed thereafter.
Immunohistology.
￿
Experiments were designed to correlate the
functional outcome of transplanted islets with the immunohisto-
logical features of infiltrating cell types. C57BL/6 mice (n = 9)
hadB10.BRislets transplanted underthe renal capsule ofboth the
left (300 islets) andright(500islets) kidneys. At 5 dpost-transplant,
a left nephrectomy was performed, and the islet-bearing portion
ofthekidney wasprocessed forhistologyas describedbelow. Blood
glucoselevels were determined daily post-transplant, and post-left
nephrectomy, to assess the functional status of the 500 allogeneic
islets (a quantity known to be sufficient to induce normoglycemia
from the isograft experiments) under the right kidney. This per-
mitted accurate correlation ofhistological features with graft func-
tion at the time of thebiopsy, post-transplant day 5, andwith the
ultimate functional outcome ofthe transplant as manifested by the
islets transplanted in the remaining kidney. Immunocytochemical
analysis ofgraft-infiltrating cells, and Ig and complement deposi-
tion, in grafts from recipients with classic rejection and primary
nonfunction were compared. The features ofislet isograft and al-
lograft biopsies taken at day 5 post-transplant in recipients that
were normoglycemic established thebaseline levelof inflammation
of lymphoid cells and macrophages.
Kidney tissue specimens that containedtransplanted islets were
snap frozen in precooled isopentane and stored at -70°C until
sectioned. Frozen tissue sections (4 /Am) were cut on a Lipshaw
cryostat, air dried, and stored in a constant temperature (25°C)
and humidity (60%) facility. Sections used for light microscopic
histologic analysis were fixedin buffered 10% formalin and stained
with periodic acid-Schiff reagents.
Methods ofimmunocytochemistry have previously been described
(25). Briefly, sections were acetone fixed and washed with PBS,
pH 7.4. Specimens evaluated for insulin-containing tissue were
reacted with guinea pig anti-human insulin (Ventrex, Inc.) and
a second layer of goat anti-guinea pig FITC-conjugated IgG (H
andL chains) (CooperBiomedical, Inc., Malvern, PA). Tissues evalu-
ated for deposition of Ig reacted with affinity-isolated FITC goat
anti-mouse IgM(p) (Tago Inc., Burlingame, CA), or goat anti-
mouseIgG (OrganonTeknika). Complement deposition was studied
using afftnity4solated goat anti-mouse C3 (OrganonTeknika)
stained with affinity-isolatedFITC rabbit anti-goatIgG(Organon-
Teknika). Phenotypic analysis of graft-infiltrating cells wasanalyzed
using rat mAbs against murine Thy-1.2, CD4, CD8, and Mac-1
from cell lines obtained from American Type Culture Collection.
Thesewere overlaid with affinity-purified, mouseserum-adsorbed,
FITC-F(ab')z goat anti-rat IgG (Pel-Freeze Biologicals, Rogers,
AR) and washed with PBS. Amplification was achieved by the
use of a second FITC-conjugated reagent, affinity-isolated, mouse
serum-adsorbed, F(ab')a rabbit anti-goat IgG (OrganonTeknika).
Afterafinal PBSwash, ethidiumbromidewas appliedto stainnuclei,
and p-phenylenediamine to retard fluorescence fading (26). Con-
trol sections of each tissue were prepared as above, omitting pri-
mary antibody, and using appropriate second and third layers of
FITC-labeled antibodies and ethidium bromide andp-phenylene-
diamine.
Functional Outcome andAnalysis ofData.
￿
Long-termacceptance
of an islet graft was defined as induction and persistence of nor-
moglycemia (nonfasting blood glucose <200 mg/dl) for >100 d
post-transplant in therecipient, classic rejection as reversion to glu-cose >250 mg/dl after a period of transient normoglycemia, and
primary nonfunction as glucose persistently >200 mg/dl. In mice
with long-term acceptance, confirmation that the grafts were
responsible for normoglycemia was accomplished by demonstrating
hyperglycemia after nephrectomy of the islet-bearing kidney. Mean
values are given with SDs and numbers of animals in groups, and
student's t test was used to determine the significance of the differ-
ences in mean values. The Wilcoxon test was used to determine
the significance of differences in overall allograft functional sur-
vival times between groups. The Xz test was used to determine
the significance of differences in proportions of the various out-
comes between groups.
Results
Number of Islets Required and Time Course for Reversal of
Streptozotocin-induced Diabetes. We determined the minimal
number of islets required to reverse streptozotocin-induced
diabetes, and the dose-response relationship between the
number of islets implanted and the time post-transplant for
amelioration of the diabetic state (glucose <200 mg/dl) (Fig.
1, A and B). Beyond a threshold of 300 islets, the number
of islets transplanted did not influence the ultimate outcome
in isograft recipients, and failure to reverse the diabetic state
due to technical problems did not occur with implantation
of >300 islets. The time between transplantation and graft
function producing normoglycemia varied inversely with the
number of islets implanted up to 600 islets. Transplantation
of 600-900 (n = 16) islets brought about normoglycemia
in all syngeneic recipients between 1 and 5 d (mean 2.4 ±
1.7 d), and all became permanently normoglycemic. There-
fore, in the experiments described below, each recipient was
transplanted with between 600 and 900 islets.
Functional Outcomes ofIslet Allotransplantation.
￿
The func-
tional outcomes of allogeneic islet transplants in both direc-
tionsbetween the B10.BR and C57BL/6 strains were classified
into three groups: primary nonfunction, classic rejection, and
spontaneous long-term functional acceptance. Primary non-
function was defined as glucose persistently >200 mg/dl,
classic rejection as reversion to glucose >250 mg/dl after a
period of transient normoglycemia (nonfasting blood glu-
cose <200 mg/dl for at least 2 d), and spontaneous long-term
acceptance as permanent (>100 d) normoglycemia. The fre-
quency distributions of the various outcomes (Table 1) was
comparedbetween a series of26 islet transplants from C57BL/6
donors to B10.BR recipients(mean 669 t 57 islets/recipient),
and 39 transplants from B10.BR donors to C57BL/6 recipients
(mean 722 ± 94 islets/recipient). The mean number ofislets
per recipient was similar in both directions (p > 0.41).
In the C57BL/6 (donor) to B10.BR (recipient) combina-
tion, primary nonfunction occurred in two (8%), classic re-
jection in six (23%) at a mean time of 23.8 ± 7.8 d post-
transplant, and spontaneous long-term graft acceptance in
18 (69%). The number of islets transplanted were similar
in the three recipient subgroups exhibiting the various out-
comes: 700 ± 0 (n = 2), 667 ± 75 (n = 6), and 667 ±
54 (n = 18), respectively (p > 0.35 for all comparisons). The
mean functional survival time for C57BL/6 islets in all B10.BR
293
￿
Kaufman et al.
Number of Islets Transplanted
Figure 1.
￿
(A) Dose-response curve defining the threshold number
of isologous islets resulting in permanent amelioration of diabetes
when transplanted under the renal capsule. Recipient C57BL/6 and
B10.BR strain mice, made diabetic with streptozotocin, were trans-
planted with isologous islets to the left renal subcapsular space. 38
diabetic mice (23 B10.BR; 15 C57BL/6) divided into seven groups of
five to seven mice received 100-900 hand-picked islets free of con-
taminating acinar and lymphoid tissue. Diabetes was ameliorated with
grafts of 100 islets in one of five cases (20%), and with grafts of 200
islets in four of five (80%) recipients, whereas grafts of 300 (n - 5),
500 (n - 7), 750 (n a 6), or 900 (n - 5) islets reversed the dia-
betic state in 28 of 28 cases (100%). Removal of the islet isograft
always resulted in recurrence of hyperglycemia, proving that glucose
control depended on the transplanted islets. (B) The relationship be-
tween the number of transplanted isologous islets that will ameliorate
diabetes and the time (d) post-transplant when permanent reversion
to normoglycemia (blood glucose <200 mg/dl) occurs. Recipient
mice, made diabetic with streptozotocin, were transplanted with var-
ious numbers of isolated isologous islets to the left renal subcapsular
space. Recipients of 300 isologous islets (n - 5) became permanently
normoglycemic at a mean time of 13.2 ± 4.7 d post-transplant, and
recipients of 500 islets (n = 7) at a mean time of 7.3 ± 6.7 d.
Recipients of 600 islets (n
￿
5) became normoglycemic at a mean
time of 2.6 t 1.8 d, and transplantation of larger numbers of islets,
up to 900, did not further reduce the time post-transplant to nor-
moglycemia.
recipients was 74.7 ± 39.3 d (primary nonfunction counted
as 0 d offunction, and long-term acceptance counted as 100 d).
For islet transplants from B10.BR donors to C57BL/6
recipients, the mean functional survival time was 28.3 ± 40.8
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￿
Outcome of Islet Allografts between C57BL/6 (H-2b) and B10.BR (H-2k) Mice
Duration
￿
Islet graft
￿
No . with primary
￿
No.
￿
No. surviving
Recipient
￿
Donor
￿
n
￿
of function
￿
survival
￿
nonfunction
￿
rejecting
￿
long term
mean d ± SD
￿
d
￿
mean day ± SD
C57BL/6
￿
B10.BR
￿
26
￿
74.7 ± 39.3
￿
0x2, 13, 17,
￿
2 (8%)"
￿
6 (23%)
￿
18 (69%)"
23, 26, 32x2,
￿
23 .8 ± 7.8
>100x18
B10.BR
￿
C57BL/6
￿
39
￿
28.3 ± 40.8'
￿
0x18, 7, 9x2,
￿
18 (46%)'
￿
12 (31%)
￿
9 (23%)"
11x2, 15, 16,
￿
16 .8 ± 9.1
18x2, 22, 27,
39, >100x9
Recipient mice were made diabetic by a single intraperitoneal injection of streptozotocin, and donor islets were transplanted beneath the left
kidney capsule . Blood glucose levels were determined thrice weekly (see Materials and Methods). Long-term survival was defined as permanent
(>100 d) normoglycemia (nonfasting blood glucose <200 mg/dl for at least 2 d), rejection as reversion to glucose >250 mg/dl after a period
of transient normoglycemia, and primary nonfunction as glucose persistently >200 mg/dl. For mean survival time, primary nonfunction was
counted as 0 d of function, long-term acceptance was counted as 100 d, and for those undergoing classic rejection, the time to rejection was
counted as the survival time.
p < 0.001, student's t test.
d, significantly less than in the reciprocal direction (74.7 t
39.3 d, p < 0.001). The three possible outcomes also had
a significantly different frequency distribution in C57BL/6
recipients of B10.BR islets than in the reciprocal direction
(p < 0.001 for overall comparison). Primary nonfunction oc-
curred in 18 (46%), classic rejection in 12 (31%), and long-
term acceptance in nine (23%), again with no significant differ-
ences in the mean number of B10.BR islets transplanted in
the three C57BL/6 recipient outcome subgroups: 704 t 81
(n = 18), 740 ± 99 (n = 12), and 733 ± 115 (n = 9) islets
per recipient (p > 0.45). Although the incidence of classic
rejection was similar in both directions (p = 0.51), the inci-
dence of primary nonfunction was significantly higher (p <
0.001) and the incidence of spontaneous long-term acceptance
significantly lower (p < 0.001) in C57BL/6 recipients of
B10.BR islet allografts, than in B10.BR recipients of C57BL/6
islet allografts. In the classic rejection subgroups, the mean
duration of graft function was 16.8 t 9.1 d post-transplant
in the C57BL/6 recipients ofB10.BR islets, not significantly
shorter (p = 0.128) than the mean duration offunction, 23.8
± 7 .8 d post-transplant, in the reciprocal direction.
The total graft failure rate (primary nonfunction plus classic
rejection) of 77% (30:39) in the C57BL/6 recipients of
B10.BR islets was significantly higher (p < 0.001) than the
total failure rate of 31% (8:26) in B10.BR recipients of
C57BL/6 islets. Neither the number of B10.BR islets trans-
planted nor the recipient pre-transplant glucose values in the
C57BL/6 recipients correlated with the incidences ofprimary
nonfunction, classic rejection, and long-term acceptance (Table
2). The proportions of the various transplant outcomes were
not statistically significantly different when stratifiedfor islet
dose (600-700 and 701-900) or according to recipient pre-
transplant blood glucose level (350-450 and >451 mg/dl).
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In addition, logistic regression analysis of the combined
influences of the number of islets transplanted and the recip-
ient pre-transplant glucose level showed no statistically sig-
nificant effect on the incidence of primary nonfunction.
Effect of Cyclosporine on Islet Allograft Primary Nonfunction
and Long-term Acceptance. Cyclosporine was administered to
recipient mice to probefor a possible role of the alloimmune
response as a cause of primary nonfunction. A dose-response
study was conducted whereby C57BL/6 recipientsofB10.BR
islets were given cyclosporine at doses of 5-10 mg/kg/d (low
dose, n = 16), or 20-60 mg/kg/d (high dose, n = 14), for
100 d.
A nonimmunosuppressed control group of 30 C57BL/6
recipients of B103R islets demonstrated a mean islet allograft
functional survival time of 31.6 t 42.5 d, similar to that
observed for the 39 C57BL/6 recipients of B10.BR islets in
the previous series (mean functional survival time 28.3 t
40.8 d; p = 0.581). In the controls, the proportions of
recipients with each of the three functional outcomes were
nearly identical to the proportions observed in the initial islet
allograft experiments using the B10.BR donor to C57BL/6
recipient combination. In the controls of the present experi-
ment, primary nonfunction occurred in 11(37%), classic re-
jection in 11(37%) at a mean of 13.5 ± 4.9 d post-transplant,
and spontaneous long-term acceptance in eight (26%). Again,
the mean of the number of islets was similar in the three
outcome groups, 673 t 70 (n = 11), 698 t 72 (n = 11),
and 679 ± 42 (n = 8) islets per recipient, respectively
(p > 0.65).
Islet allografts in recipients given high-dose ryclosporine
(n = 14) had a significantly longer (p < 0.03) overall dura-
tion offunction (mean survival 57.1 ± 45.0 d) than the nonim-
munosuppressed control recipients (mean survival 31.6 ± 42.5Table 2.
￿
Functional Outcome of Islet Allografts (BIO.BR to
C57BL/6) as Related to the Number of Islets Transplanted and
Recipient Pretransplant Blood Glucose
600-700
Outcome
￿
(n = 23)
No. of islets transplanted'
% n
￿
%
Primary nonfunction
￿
52 (12)
￿
37
Classical rejection
￿
26
￿
(6)
￿
37
Long-term acceptance
￿
22
￿
(5)
￿
26
701-900
(n = 16)
Pre-transplant blood glucose value#
350-450
mg/dl
(n = 20)
n
￿
%
Primary nonfunction
￿
45
￿
(9)
￿
47
Classical rejection
￿
35
￿
(7)
￿
26
Long-term acceptance
￿
20
￿
(4)
￿
26
>451 mg/dl
(n = 19)
Overall distribution: X2, 0.88; p - 0.64. Incidence of primary
nonfunction: p - 0.54 (student's t test).
t Overall distribution: X2, 0.42; p - 0.81. Incidence of primary
nonfunction: p - 0.89 (student's t test).
n
(6)
(6)
(4)
n
(9)
(5)
(5)
d). The overall duration of function was also significantly
longer (p < 0.002) in the high-dose than in the low-dose
cyclosporine group (mean survival 11.7 ± 24.6 d), while the
survival time of the low-dose and the control group did not
differ significantly (p > 0.09).
Primary nonfunction occurred in only one (7%) of the
14 recipients given high-dose cyclosporine, an incidence
significantly lower (p = 0.041) than the 37% incidence in
the control group, as well as that of the low-dose cyclospo-
rine group (Table 3). In the latter group, 8 (50%) of 16 re-
cipients exhibited primary nonfunction, not significantly
different from the incidence in the control group. Classic re-
jection occurred in six (43%) of the recipients given high-
dose cyclosporine, at a mean of 16.5 ± 6.9 d after transplan-
tation, similar to the incidences of classic rejection and mean
times of rejection in the control group (incidence 37%, at
a mean of 13.5 t 4.9 d post-transplant), and in the low-dose
cyclosporine group (incidence 44%, at a mean of 12.4 t 5.4
d post-transplant). Spontaneous long-term acceptance occurred
in seven (50%) of the recipients given high-dose cyclosporine
vs. one (6%) of the low-dose cyclosporine group (p < 0.05),
and vs. eight (26%) in the untreated controls (p = 0.134).
Cyclosporine did not influence the course of diabetes in
nontransplanted animals, or functional survival of islets in
isograft recipients. Diabetic mice administered 20 mg/kg/d
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cyclosporine and not transplanted remained hyperglycemic.
The isograft controls (n = 5) given 20 mg/kg/d cyclospo-
rine remained euglycemic for >100 d.
Histology and Immunopathology ofIslet Grafts.
￿
On day 5
post-transplant, histological examination of the C57BL/6 islet
isografts and ofB10.BR islet allograftsin C57BL/6 recipients
that were normoglycemic revealed infiltration by lympho-
cytes, macrophages, and fibroblasts between the renal cap-
sule and the islets. At this time the morphological differ-
ences between isografts and allografts were minimal. Of the
three allograft recipients with islets under both kidney cap-
sules who were normoglycemic and who had one kidney re-
moved at day 5, two developed classic rejection and one spon-
taneous long-term acceptance. The infiltrating cells did not
disrupt the architecture of the islets and were not insinuated
between the islets and the renal parenchyma. However,
prospective histological examination of islet grafts taken from
one kidney site on day 5 from recipients with primary non-
function that had been transplanted with islets under both
kidney capsules showed a higher number of Mac-1+ cells.
Surviving allografts examined >100 d post-transplant showed
no inflammatory infiltrate.
Biopsies taken within 3 d of reversion to hyperglycemia
in C57BL/6 recipients of B10.BR islet allografts with classic
rejection demonstrated intense infiltration of lymphoid cells
that disrupted the architecture of the islets, leaving only small
remnants ofinsulin-containing tissue (Fig. 2, A and B). The
infiltrate consisted of Thy-1+ and IIT2-R+ cells and a rela-
tive paucity of Mac-1+ cells (Fig. 2, C and D). The concen-
tration of CD4+ and CD8+ cells infiltrating grafts taken
from recipientsexhibiting classic rejection was nearly double
that observed in grafts from recipients with primary non-
function (Table 4).
Histological examination on day 5 of islet grafts from
recipients with primary nonfunction showed a moderate
inflammatory cell infiltrate circumscribing large clusters of
insulin-positive cells within what appeared to be viable islets.
The infiltratewas composed ofapproximately equal propor-
tions of Thy-1+ lymphoid cells and large Mac-1+ mononu-
clearcells (Fig. 3, A-D). The infiltrate in recipientsexhibiting
primary nonfunction was more intense than that observed
in recipients of isografts or in recipientsofallograftsthat were
normoglycemic on day 5 post-transplant. The concentra-
tion of Mac-1+ cells in the infiltrate of grafts with primary
nonfunction on day 5 was also higher than that observed
in the grafts removed from recipients undergoing classic
rejection.
Ig and complement were not observed in islet allografts
from recipients exhibiting either primary nonfunction or re-
jection. Additionally, when sera from C57BL/6 recipients
with primary nonfunction (n = 3) were layered on freshly
isolated B10.BR islets, the presence ofantiislet antibody depo-
sition could not be detected.
These findings suggested that islet allograft primary non-
function is associated with a prominent infiltration of Mac-
1+ cells, whereas in classic rejection, Thy-1+, CD4+, CD8+,
and Ih2-R+ T cells dominated.Table 3.
￿
Outcome of B10.BR Islet Allografts Tranplanted to Normal and to Immunosuppressed C57BL/6 Mice
The p values were as follows: a, 0.05; b, 0.02; c, 0.003; d, 0.002; e, 0.041; f, 0.024; g, 0.05; h, 0.024; i, 0.017; j, 0.03; k, 0.03; 1, 0.03;
m, 0.001; n, 0.134; o, 0.05 (student's t tests).
' C57BL/6 allograft recipients were treated with cyclosporine (20 mg/ml dissolved in olive oil) administered subcutaneously (20-60 mg/kg/d
or 5-10 mg/kg/d) beginning at the time of transplant and daily thereafter for 100 d.
t C57BL/6 allograft recipients were treated with silica (10 mg/ml dissolved in saline solution) administered intraperitoneally (1 mg/d for 5 d)
beginning 4 wk before transplantation . Induction of diabetes and subsequent islet transplantation were conducted thereafter.
Effect ofMacrophageDepletion on IsletAllograft Primary Non-
function and Classic Rejection. Immunofluorescence analysis
suggested an association between the presence ofmacrophages
and allograft primary nonfunction. To address the functional
role of macrophages in primary nonfunction, C57BL/6
recipients ofB10.BK islet allografts were administered silica
to deplete that cell subset. Depletion of host peritoneal mac-
rophages several weeks after administration of silica was as-
sessed by FACS analysis of peritoneal exudate cells from non-
transplanted controls (Fig. 4). The peritoneal exudate cell
population consisted of two major populations of cells dis-
tinguished by size: the smaller Thy-1+ cells and a granular,
large-cell population that consisted mostly of Mac-1+ cells.
Administration of silica depleted the large Mac-1+ cells and
changed the Mac-1/Thy-1 ratio from -1:1 to 1:8. Further-
more, the function of splenic C57BL/6 T cells as assessed
by generation of allocytotoxicity in a cell-mediated lymphol-
ysis assay ($1Cr release by labeled B10.BR blasts) was similar
in treated and untreated mice.
Although the overall duration of graft function was not
significantly different between the recipientstreated with silica
(mean 36.1 ± 34.4 d) and the untreated C57BL/6 control
recipientsofB10.BR islets, the functional outcomes occurred
in significantly different proportions (p = 0.03). Primary
nonfunction was completely abolished in recipientsgiven silica,
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an incidence of 0% (0:10) vs. 37% in controls (p = 0.024)
(Table 3). Classic rejection, however, still occurred in silica-
treated mice; the incidence was 80% (8 :10) at a mean of 20.1
± 7.8 d post-transplant, compared with the incidence of37%
(p = 0.017) at a mean of 13.5 ± 4.9 d (p = 0.034) in con-
trols. Long-term acceptance occurred with an incidence of
20% (2 :10) in silica-treated recipients, compared with the
incidence of 26% (p = 0.843) in controls. Thus, silica pre-
vented primary nonfunction, but the changes in proportions
suggested that grafts destined to fail from primary nonfunc-
tion were shifted into the classic rejection category. The total
failure rate (primary nonfunction plus classic rejection) was
74% in the controls, similar to the classic rejection rate of
80% in the silica-treated mice.
Immunodepletion of CD4 and CD8 T Lymphocytes with
mAbs. To address the role of CD4 and CD8 T lympho-
cytes in alloimmune injury of islets, C57BL/6 recipients of
B10.BR islet allografts were administered either anti-CD4
mAb (GK 1.5, rat anti-mouse IgG2b) or anti-CD8 mAb
(2.43, rat anti-mouse IgG2b). Recipient mice were given the
mAb in vivo (750 Wg i.p., on days -1, 0, 1, 3, and 5 relative
to time of islet transplantation) .
In CD4 T cell-depleted islet allograft recipients (n = 12),
the overall duration of graft function (mean 22.2 ± 25 .8 d)
was similar to that of the normal C57BL/6 controls. The
Immunosuppression n
Duration of
function Islet survival
No. with primary
nonfunction No. rejecting (n)
No. surviving
long term
mean d ± SD d mean d ± SD
None 30 31.6 ± 42.5',° 0x11, 5, 6, 11, 11 (37%)e.f 11 (37%)h.i 8 (26%)°
12, 13, 14x2, 16, (13 .5 ± 4.9y.1.1
17, 20x2, >100x8
CsA 16 11 .7 ± 24.64 0x8, 8x3, 9, 8 (50%)9 7 (44%) 1 (6%)-
(5-10 mg/kg)" 16, 18, 20, 100 (12 .4 ± 5 .4)
CsA 14 57 ± 45" 0, 7, 12, 14, 1 (7%)- 6 (43%) 7 (50%)-
(20-60 mg/kg)"' 18, 22, 26, >100x7 (16 .5 ± 6.9)
Silica# 10 36.1 ± 34.4 13, 14, 16, 17, 18 0 (0%)f 8 (80%)' 2 (20%)
19, 29, 35, 100x2 (20.1 ± 7.8y
Anti-CD4 12 22.5 ± 25.86 0x2, 13, 14x2, 17, 2 (17%) 9 (75%)h 1 (8%)
18, 19, 20, 25, 26, >100 (18.4 ± 4 .7)k .-
Anti-CD8 9 61 .2 ± 39.4',b 0x2, 56, 57, 58, 2 (22%) 4 (45%) 3 (33%)
80, >100x3 (62.8 ± 11 .5)1,-CD4 T cell-depleted islet allograft recipients had an incidence
of primary nonfunction of 17% (2:12), a lower incidence
than that of37% in controls, but not statistically significantly
different (p = 0.215) (Table 3) . Classic rejection occurred
in 9 (75%) of 12 of the CD4 T cell-depleted recipients at
a mean of 18.4 ± 4.7 d, significantly later (p = 0.033) than
in controls (Table 3) . Spontaneous long-term acceptance oc-
curred in 1(8%) of 12 ofthe CD4 immunodepleted recipients
vs. 26% in nonimmunosuppressed controls (p = 0.024) . Thus,
immunodepletion with anti-CD4 did not significantly alter
the rate ofprimary nonfunction ; however, among those mice
that classically rejected the islets, the mean time to rejection
was significantly extended.
In CD8 T cell-depleted islet allograft recipients (n = 9),
the overall duration of graft function was significantly (p <
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Figure 2 .
￿
(A) Period acid-Schiffstained
nephrectomy specimen from recurrent hyper-
glycemic C57BL/6 strain recipient of rejected
B10.BR strain allogeneic islets, day 15 post-
transplant ; (B) insulin-containing cells reactive
with guinea pig anti-human insulin and a
second layer of goat anti-guinea pig FITC-
conjugated IgG (H and L chains) ; (C) Thy-1 .2
graft-infiltrating cells of the rejected islet al-
lograft; and (D) Mac-I+ graft-infiltrating cells
of the rejected islet allograft . All tissues are
from adjacent sections (x300).
0.02) longer (mean 61.2 ± 39.4 d) than that of CD4 T
cell-depleted islet allograft recipients (mean 22.2 ± 25.8 d),
as well as significantly (p = 0.05) longer than that of the
normal C57BL/6 controls (Table 3) . However, primary non-
function occurred in two (22%) recipients depleted ofCD8+
T lymphocytes, an incidence lower than the 37% primary
nonfunction rate in control animals, but not statistically
significant (p = 0.433), and similar to the 17% primary non-
function rate in CD4T cell-depleted recipients (p = 0.215)
(Table 3) . Thus, immunodepletion with anti-CD8 did not
significantly alter the rate of primary nonfunction .
In CD8 T cell-depleted mice, classic rejection occurred
in four (45%) of nine, and at a median of 57.5 d (mean of
62.8 ± 11.5 d) post-transplant . The incidence ofclassic rejec-
tion in the CD8T cell-depleted recipients was not significantlyThe methods used for enumeration of mononuclear cell populations by indirect immunofluorescence are similar to those described in detail for
kidney (25). The method described herein was developed specifically for analysis of inflammation in islet allograft tissue. Cells were considered
"positive" that have an apple-green fluorescent plasma membrane surrounding a red-orange nucleus. The relative number of positive cells are
expressed as: volume density for each tissue - mean number of positive cells/number of grid points in microscopic fields viewed (x500) with
a 10 x 10-mm indexing grid.
different from the incidence of37% (p = 0.684) in controls,
and of 75% (9 :12) in CD4 T cell-depleted recipients. How-
ever, the mean time to rejection among the recipients that
underwent classic rejection was statistically significantly pro-
longed in CD8 T cell-depleted animals (mean of 62.8 ± 11.5
d) vs. CD4-immunodepleted animals (mean of 13.5 ± 4.9 d
[p < 0.001]), and in the untreated controls (mean 18.4 t
4.7 d [p < 0.03]). In fact, allogeneic islets transplanted to
CD8 T cell-depleted recipients were not rejected before day
56 post-transplant (Fig. 5). Thus, among those mice that clas-
sically rejected the islets, the mean time to rejection was
significantly extended compared with controls, as well as with
CD4 T cell-depleted recipients.
Although treatment with anti-CD8 significantly prolonged
islet allograft survival in recipients that ultimately rejected
the islets, it did not significantly increase the rate of long-
term (>100 d) acceptance as compared with untreated recip-
ients. Long-term acceptance occurred in three (33%) of nine
of the CD8 T cell-depleted recipients, compared with a long-
term acceptance rate of 26% (p = 0.324) in controls, and
8% (p < 0.001) in CD4 T cell-depleted recipients. It is in-
teresting to consider whether or not some islet allograftsmight
be destined to survive permanently in any circumstance. A
previous report showed that in untreated islet allograft
recipients, the variability ofallograft outcome, including long-
term acceptance, appeared to be determined to greater extent
by host factors (19), rather than immunogenic heterogeneity
of islet preparations due to fortuitous inclusion or exclusion
of nonislet nodal or ductal tissue (27).
Discussion
Persistent hyperglycemia aftertransplantation of allogeneic
islets in rodent models has been attributed to technical prob-
lems with the transplant procedure, such as implantation of
an insufficient islet mass or other nonimmunological causes
(19, 28, 29). If technical problems were the sole explanation
of primary nonfunction, then the incidence should be the
same for isologous islet transplants carried out within the
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same donor and recipient strains. Our experiments showed
that primary nonfunction ofislet allografts placed under the
renal capsule in C57BL/6 and B10.BR mice cannot be ex-
plained by technical factors. First, in 28 consecutive trans-
plants of 300-900 syngeneic islets to diabetic recipients of
both strains, not a single instance of primary nonfunction
was observed. Primary nonfunction occurred only in situa-
tions where an alloimmune response was possible. Second,
histological examination at day 5 of allogeneic islets with pri-
mary nonfunction showed viable islets containing insulin-
positive cells; engraftment occurred, but the islets simply did
not function to the extent that hyperglycemia could be amelio-
rated. A further argument against primary nonfunction being
due to technical factors, such as variability in day-to-day quality
of islet preparations, comes from our previous observations
that when groups of two to four recipientswere transplanted
with clean, hand-picked islets derived from large batchisola-
tions, the incidence of primary nonfunction within groups
did not differ from that observed in experiments in which
allogeneicislets were prepared individually for each mouse (19).
Rather, our experiments suggested that the phenomenon
of islet primary nonfunction was a manifestation of the host
alloimmune response. First, in B10.BR recipients of C57BL/6
islet allografts, there was a high incidence (69%) of sponta-
neous long-term acceptance and a low incidence (8%) ofpri-
mary nonfunction, whereas, in C57BL/6 recipients ofB10.BR
islets, the incidence of spontaneous long-term acceptance was
significantly lower (23-26%; Tables 1 and 2) and the inci-
dence of primary nonfunction was significantly higher (37-
46%, Tables 1 and 2). The contrast in the incidences is much
more likely to be due to a difference in the nature of the im-
mune responses ofthe two strains, or differences in the inher-
ent immunogenicity of islets derived from the two strains,
than to technical problems that occur in one direction but
not in the other. Second, the high incidence ofislet allograft
primary nonfunction was not a solitary finding. A high rate
of primary nonfunction in the B10.BR to C57BL/6 combi-
nation occurred in the two control groups as well as the group
Table 4. Immunocytochemical
Graft combination outcome
Analysis of Infiltrating Cell Types in
Glycemia
(post-transplant time of biopsy)
Islet
n
Grafts
Thy-1+
Mean
CD4+
no . of
CD8+
positive cells
IL-2-R+ Mac-1+
Isograft Normoglycemia (day 5) 3 50 22 17 5 62
Allograft Normoglycemia (day 5) 3 49 32 18 7 49
Allograft primary nonfunction Hyperglycemia (day 5) 3 67 33 27 6 81
Allograft classical rejection Hyperglycemia (day 15-23) 3 97 62 51 21 24
Allograft long-term acceptance Normoglycemia (day 100) 3 12 9 5 1 9receiving low-dose cyclosporine (5-10 mg/kg/d), demon-
strating the reproducibility of the phenomenon . Third, im-
munosuppression of the C57BL/6 recipients with high-dose
cyclosporine (20-60 mg/kd/d) reduced the incidence of pri-
mary nonfunction from 37 to 7% (p < 0.05), while also in-
creasing the long-term functional graft survival rate from 26
to50%. Anti-CD4 and anti-CD8 treatment reduced the rate
of primary nonfunction, though not to the degree that cy-
closporine did. Finally, the use of the antimacrophage agent,
silica, completely abolished primary nonfunction, suggesting
a dominant role for macrophages or activated macrophage
byproducts, that either directly injured the allogeneic islets,
or inhibited function until ultimate destruction was medi-
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Figure 3 .
￿
(A) Period acid-Schiff-stained
nephrectomy specimen from persistently
hyperglycemic C57BL/6 strain recipient ex-
hibiting primary nonfunction of B10.BR
strain allogeneic islets, day 5 post-transplant ;
(B) insulin-containing cells reactive with
guinea pig anti-human insulin and a second
layer of goat anti-guinea pig FITC-conju-
gated IgG (H and L chains) in an islet al-
lograft specimen from a recipient exhibiting
primary nonfunction; (C) Thy-1.2+ graft-
infiltrating cells of an islet allograft with pri-
mary nonfunction; and (D) Mac-l' graft-
infiltrating cells of an islet allograft with
primary nonfunction . All tissues are from ad-
jacent sections (x300) .
ated by the CD4+ and CD8+ T cells that are operative in
classic rejection .
The use of an antimacrophage treatment in islet allograft
recipients was preceded by the histologic and immunopatho-
logic findings suggesting that primary nonfunction was a
cell-mediated phenomenon dominated by macrophages. Im-
munofluorescence analysis of grafts with primary nonfunc-
tion showed the concentration ofT lymphocytes in the cel-
lular infiltrate to be lower, and of macrophages to be higher,
relative to the proportions ofT lymphocytes and macrophages
infiltrating grafts from recipients that underwent classic re-
jection. The term "nonfunction" appeared apt since the islets
contained insulin despite hyperglycemia. The presence ofmac-rophages per se may not be critical, since Mac-1+ cells were
also observed in isografts on day 5, although not in the con-
centration seen in allografts that underwent primary non-
function, but macrophages encountering allo-antigens may
function differently from, or release byproducts not released
by, those in a syngeneic environment .
The specific immune mechanisms responsible for islet al-
lograft primary nonfunction appeared not to be humorally
mediated . Ig and complement were not detected in islet grafts
from recipients exhibiting primary nonfunction, nor did the
serum of such mice react with allogeneic B10.BR islets in
tissue sections. We hypothesize that primary nonfunction
resulted from a cell-mediated response involving mediators
of rapid onset, macrophages, or macrophage byproducts, that
either directly injured the islets, or inhibited function until
ultimate destruction was incurred by those mediators of rel-
atively delayed onset, CD4+ and CD8+ T cells, that are
operative in classic rejection .
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Figure 4 .
￿
FACS analysis of peritoneal exudate cells in normal
C57BL/6 mice (A) and mice administered intraperitoneal silica 3-4
wk previously (B) . Cells were analyzed according to size (forward
scatter) and granularity (side scatter) on a FACS IV (Becton Dick-
inson & Co.) equipped with an argon laser, and the data were ana-
lyzed on a Digital PDP 11/73 computer with specialized software
jointly developed by Becton Dickinson & Co . and the NIH . Encir-
cled areas demonstrate RBC (a), T lymphocyte (b), and macrophage
(c) populations . The relative proportion of each cell population in a
representative normal control animal was: a, 2.9% ; b, 52.6%, and c,
44.5% ; in a silica treated animal : a, 6.2% ; b, 82.4% ; and c, 11.4% .
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Figure 5 .
￿
Percent survival of islet allografts among the subsets of
recipients exhibiting classic rejection. Recipient groups include non-
treated controls, and recipients immunodepleted of CD4 and CD8 T
lymphocytes, or treated with silica to modulate macrophage function .
Islet Allograft Primary Nonfunction
Similar observations of the association of macrophage in-
filtration of islets in animal models of spontaneous autoim-
mune diabetes have been reported (30, 31) . If macrophage
infiltration causes islet graft dysfunction in autoimmune dia-
betes, then our observations would provide correlative evi-
dence of macrophage-associated injury in the allograft situa-
tion. Injury ofallogeneic islets might be caused by secretion
of monokines, such as IL1 and TNF, which perturb insulin
biosynthesis in and secretion from rodent islets in vitro (32-
35) . Macrophages have also been reported to cause sponta-
neous cytotoxicity of islets in vitro (36, 37) . Moreover, IL1
secretion from macrophages has been shown in some models
(38-40) to be inhibited by cyclosporine, an observation that
would appear to fit with our own in themouse islet allograft
model . However, the complex effects ofcyclosporine on mac-
rophage function are incompletely known, and others have
shown ILl production by macrophages to be unaffected by
cyclosporine (41) .
The possible involvement ofmacrophage-mediated injury
of allogeneic islets was tested by depletion ofperitoneal mac-
rophages before transplantation ofB10.BR islets intoC57BL/6
recipients. This treatment completely abolished primary non-
function, whereas classic rejection occurred with an incidence
of80% . This result was consistent with the hypothesis that
islet allograft primary nonfunction may be mediated, at least
in part, by macrophages, through mechanisms that are different
from conventional CD4+ or CD8+ T cell-mediated destruc-
tion that are operative in classic rejection . That primary non-
function was confined to allogeneic islets may be a conse-
quence ofdependence of macrophage activation on allo-reactive
CD4+ T cells, perhaps via secretion of IFN-y .
It is likely that, in some recipients exhibiting primary non-
function, classic rejection mechanisms eventually destroyed
the islets. If so, primary nonfunctionmay be an epi-immune
phenomenon, in which lymphokines such as IIrl inhibit islet
function while the cascade of events culminating in rejection
are gaining more mention . The mechanisms ofprimary non-
functionmay also differ in individual animals. Anti-CD8 an-
tibody treatment markedly extended survival of some grafts
before onset ofclassic rejection occurred. Indeed, the earliest
time of classic rejection in animals treated with anti-CD8
antibody was day 56 post-transplant . This interval should
give sufficient time for at least temporary engraftment of all
islet allografts, or recovery from the insulin-inhibiting func-
tion. However, even in anti-C138-treated recipients, primary
nonfunction occurred with an incidence of 22%, suggesting
that the mechanism resulting in primary nonfunction can
be sustained for a long time, or that early destruction and
not merely inhibition of function is responsible for some cases
of primary nonfunction .
Overall, the statistical analysis and functional/histological
correlations demonstrate that islet allograft primary nonfunc-
tion is a consequence of host alloimmunity, rather than being
technical in nature. This phenomenonmay be a basic biolog-
ical feature of murine allotransplantation ofislets to the renal
subcapsular space, and perhaps of islet allotransplantation in
other species . The experimental findings have clinical impli-
cations as well . To date, there has been only one documentedreport of a human islet allograft attaining sufficient function
to allow sustainedwithdrawal of exogenous insulin therapy.
Reasons offeredforthe failures have included transplantation
of an inadequate mass of viable islets (5, 6), or islet injury
by exocrine enzymes ofcontaminatingpancreatic acinar cells
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